WHO Model Formulary: Global Standards for Essential Generic Medicines
Dec, 8 2025
The WHO Model Formulary isn’t a list you find on a hospital shelf or in an insurance plan. It’s the world’s most trusted blueprint for what medicines every country - rich or poor - should have available to save lives. Developed by the World Health Organization, it’s not about profit, marketing, or convenience. It’s about survival. Every two years, a panel of 25 independent experts from 18 countries reviews hundreds of medicines to decide which ones are truly essential. Their goal? Make sure the most effective, safest, and cheapest treatments reach people who need them most - especially in places where resources are thin and supply chains break down.
What Makes a Medicine ‘Essential’?
The WHO doesn’t pick medicines based on popularity or how much a company spends on ads. They use strict, science-backed rules. To be included, a medicine must prove it works in high-quality clinical trials, is safe for widespread use, and costs less than alternatives - ideally, under three times the country’s GDP per capita per quality-adjusted life year gained. It also has to treat a disease that affects at least 100 people per 100,000. That means no niche drugs for rare conditions. Only those that impact millions.
The 2023 list includes 591 medicines covering 369 diseases. Nearly half - 49% - are antibiotics, antivirals, or antifungals. Another 22% treat heart disease, 12% fight cancer. And 46% of all listed medicines are generics. That’s not an accident. The WHO knows brand-name drugs often cost 10 to 100 times more. Generics make treatment possible for low-income families and strained health systems.
Core vs. Complementary: Two Lists, One Goal
The WHO Model List splits medicines into two groups. The core list contains the minimum needed for a basic health system - medicines that work with little to no special equipment or training. Think insulin for diabetes, penicillin for infections, or artemisinin for malaria. These should be available in every clinic, even in remote villages.
The complementary list includes medicines that need more support: specialized diagnostics, trained staff, or monitoring. Examples: cancer drugs requiring lab tests, or antiretrovirals needing regular blood checks. These aren’t less important - they’re just harder to deliver. Countries use the core list first. The complementary list helps them build up over time.
Why Generics? The Real Cost of Saving Lives
Generic medicines aren’t second-rate. They’re the same active ingredient, made to the same strict standards, just without the brand name. The WHO requires every generic on its list to meet WHO Prequalification - meaning it passes tests for purity, strength, and how well the body absorbs it. For most drugs, bioequivalence must be between 80% and 125% of the original. For narrow-therapeutic-index drugs like warfarin or lithium, the range tightens to 90-111%.
This isn’t theoretical. Since 2008, the price of generic HIV drugs has dropped by 89%, from $1,076 to just $119 per patient per year. That’s why treatment has scaled from 800,000 people in 2003 to nearly 30 million today. In Ghana, adopting the WHO list cut out-of-pocket medicine spending by 29% between 2018 and 2022. In India, hospitals using WHO-recommended antibiotic tiers slashed antimicrobial costs by 35%.
But here’s the catch: having the right medicines on paper doesn’t mean they’re in the pharmacy. In Nigeria, a 2022 survey found only 41% of essential medicines were consistently available. Stockouts lasted an average of 58 days per drug - not because the list was wrong, but because supply chains collapsed. Poor storage, corruption, and lack of funding are the real enemies.
How It Compares to National and Insurance Formularies
Don’t confuse the WHO Model List with your local hospital formulary or Medicare Part D. US insurance plans divide drugs into tiers - Tier 1 (cheap generics), Tier 5 (expensive specialty drugs) - with different co-pays for each. The WHO doesn’t care about co-pays. It cares about access. It doesn’t require five drugs per category. If one drug is clearly best, that’s the one listed.
Hospital formularies in the US are shaped by pharmacy committees, drug reps, and contracts. The WHO list is shaped by data. Only 22% of US hospital pharmacy directors regularly check the WHO list, according to a 2023 ASHP survey. They rely on Micromedex or Lexicomp instead. That’s fine for American hospitals - but it means global health leaders are often working from a different playbook.
High-income countries use the WHO list as a reference for global programs - like treating refugees or supporting clinics in Africa - but rarely for domestic decisions. Low- and middle-income countries? They build their national lists directly from it. Over 150 countries have done so. In Africa, 92% have national essential medicines lists based on the WHO model. In the Americas, it’s 68%.
Challenges and Controversies
The WHO Model List isn’t perfect. Critics point out that only 12% of new drugs approved between 2018 and 2022 made it onto the 2023 list. In comparison, high-income countries add 35-45% of new drugs to their formularies. That’s because the WHO waits for long-term safety data and real-world cost-effectiveness - not just early trial results.
Another concern: 45% of the clinical evidence used in 2023 came from industry-funded studies, up from 28% in 2015. Some experts worry this could influence decisions. The WHO says it now requires full financial disclosures from all committee members - and 100% compliance was reported in 2023.
Then there’s the problem of substandard drugs. WHO surveillance found that 10.5% of essential medicine samples in low- and middle-income countries were fake or poorly made - mostly antibiotics and antimalarials. Even if the list says “use this generic,” it doesn’t stop counterfeiters from flooding markets.
And while the list pushes for pediatric formulations, many still lack child-friendly dosing. A 2022 survey of health workers in 47 countries showed they rated the list 4.2 out of 5 for guiding choices - but only 2.8 out of 5 for helping them actually get the drugs to patients.
The Bigger Picture: Access, Not Just Availability
The WHO Model Formulary has driven $15.8 billion in global medicine procurement through UN agencies and global health funds. Eighty-five percent of Global Fund purchases follow its recommendations. Generic manufacturers now chase WHO Prequalification because it opens doors to public tenders - and that’s good. Between 2018 and 2023, the number of prequalified generic products jumped 47%.
But the real test is sustainability. Only 31% of low-income countries spend more than 15% of their health budget on medicines - the level the WHO says is needed to keep supplies flowing. Without funding, even the best list is just a document.
The WHO is adapting. The 2023 update added seven biosimilars for cancer and autoimmune diseases. Forty-two percent of listed medicines now have child-friendly versions, up from 29% in 2019. In September 2023, they launched the WHO Essential Medicines App - downloaded over 127,000 times in 158 countries. It lets pharmacists and doctors check availability, dosing, and alternatives on the go.
By 2030, the goal is to raise essential medicine availability in primary care from 65% to 80%. That’s ambitious. But without addressing supply chains, financing, and counterfeit drugs, it won’t happen.
What This Means for You
If you’re a policymaker in a low-income country, the WHO Model List is your roadmap. Use it to build your national list, prioritize procurement, and negotiate prices with suppliers. If you’re a pharmacist, push for WHO-prequalified generics - they’re the only ones guaranteed to work. If you’re a donor or global health worker, fund the systems behind the list - not just the drugs.
The truth is, the WHO Model Formulary doesn’t fix broken health systems. But it gives them a fighting chance. It says: no one should die because they can’t afford a pill that costs $2 instead of $200. That’s not just policy. That’s justice.
Is the WHO Model Formulary the same as a national formulary?
No. The WHO Model List is a global recommendation for which medicines should be considered essential. National formularies are country-specific lists that adapt the WHO guidance based on local disease patterns, funding, and infrastructure. Over 150 countries use the WHO list as a starting point, but each modifies it to fit their needs.
Are all medicines on the WHO list generics?
No. About 46% of the 591 medicines on the 2023 list are generics. The rest include brand-name drugs, biosimilars, and combination products. The WHO prioritizes affordability, so generics are heavily favored - but if a brand-name drug is the only effective option, it’s included.
How does WHO ensure generic medicines are safe?
All generics on the WHO Model List must meet WHO Prequalification standards or approval from a stringent regulatory authority like the FDA or EMA. They must pass bioequivalence testing - showing their absorption in the body matches the original drug within strict limits (80-125%, tighter for critical drugs). The WHO also monitors the market for substandard or falsified products.
Why aren’t more new drugs on the WHO list?
The WHO waits for strong, long-term evidence of safety, effectiveness, and cost-effectiveness. New drugs often lack real-world data, especially in low-resource settings. While high-income countries may approve drugs based on early trials, the WHO prioritizes proven impact over novelty. Only 12% of new drugs approved between 2018-2022 made it onto the 2023 list.
Can the WHO Model List help reduce healthcare costs?
Yes. Countries that adopt the WHO list consistently see 23-37% lower pharmaceutical spending while maintaining or improving health outcomes. By focusing on generics and eliminating expensive, low-value drugs, governments redirect funds to where they matter most - like training staff, fixing supply chains, and expanding coverage.
Raja Herbal
December 10, 2025 AT 11:49So the WHO says generics are the way to go, but in India, we still see pharmacies selling fake antibiotics like they’re candy. I’ve seen grandmas buy ‘amoxicillin’ that’s just lactose and glitter. The list is perfect on paper - but if your village clinic has no fridge and the guy behind the counter doesn’t know what ‘bioequivalence’ means, what’s the point? 🤷♂️
Iris Carmen
December 11, 2025 AT 12:45ok but why do all the fancy drugs cost 10x more if theyre literally the same chem stuff?? like i get brand names are for marketing but come on. my aunt took the generic omeprazole and swore it didnt work… until she realized she was taking the wrong pill. lol. 🤭
Rich Paul
December 13, 2025 AT 07:47Let’s be real - the WHO list is basically a glorified bulk-buying guide for NGOs. The bioequivalence thresholds? 80-125%? That’s a 45% window! You could have a drug that’s half as potent and still pass. And don’t get me started on the industry-funded studies. 45% of the data? That’s not science, that’s corporate sponsorship with a UN stamp. If you want real safety, you need FDA or EMA-tier oversight - not ‘WHO prequalified’ which is basically ‘we checked the label and it wasn’t expired.’
Delaine Kiara
December 13, 2025 AT 11:30Okay but imagine if your kid had asthma and the only inhaler that worked was $200… but the WHO said ‘nah, this $2 generic works fine’ - except it doesn’t because it’s been sitting in a warehouse in Lagos for 3 years with no AC? I’m not saying brand-name drugs are better - I’m saying the system is broken. And people are dying because we’re too busy debating bioequivalence to fix the damn supply chain. 😭
Ruth Witte
December 15, 2025 AT 05:44THIS IS WHY WE NEED TO SUPPORT GLOBAL HEALTH! 🌍💖 The WHO list is basically a superhero cape for millions who can’t afford to be sick. Every time a generic HIV drug drops from $1,000 to $100? That’s a life saved. Every time a mom in rural Kenya gets penicillin instead of nothing? That’s justice. Let’s not overcomplicate it - this list is hope in pill form. 🙌💊 #EssentialMedicinesForAll
Noah Raines
December 17, 2025 AT 04:49Look, if you think the US hospital formulary is better, you’re delusional. We have tiered systems where insurers make you try 3 cheap drugs before letting you take the one that actually works. The WHO doesn’t care about your co-pay - it cares if you live. End of story. And yeah, generics aren’t perfect - but they’re 90% better than nothing. Stop acting like your insurance plan is the pinnacle of human achievement.
Katherine Rodgers
December 17, 2025 AT 10:31Oh wow, the WHO’s ‘science-backed’ list is based on industry-funded studies? Shocking. 🙄 And now they’re adding biosimilars like it’s a new trend? Newsflash - biosimilars are just branded drugs with a different label. They cost 20% less? That’s not saving lives, that’s corporate rebranding. And 46% generics? That’s not a win - it’s a concession. The real issue? The WHO doesn’t regulate manufacturing. They just say ‘here’s the list’ and hope for the best. Meanwhile, fake malaria pills are killing kids in Nigeria. This isn’t a blueprint. It’s a fantasy.
Gilbert Lacasandile
December 17, 2025 AT 17:28I think the WHO list is a great starting point, and honestly, most countries should use it as a foundation. But I also get why places like the US don’t follow it strictly - our disease burden and infrastructure are different. Maybe the real solution is adapting the list locally instead of forcing it globally? Just saying - maybe we need both: global standards and local flexibility.
Lola Bchoudi
December 18, 2025 AT 02:22Let’s reframe this: the WHO Model Formulary isn’t just a drug list - it’s a systems design document. It’s telling low-resource settings: ‘Here’s your minimum viable product for health equity.’ You don’t need 15 different antihypertensives - you need one that works, is cheap, and can be stored without refrigeration. That’s not limiting - that’s smart. And if your country can’t even get penicillin to 80% of your population, worrying about biosimilars is putting the cart before the horse. Focus on supply chains first. Then scale.
Kathy Haverly
December 18, 2025 AT 18:06They say 150 countries use it - but how many of those are just copying it because the World Bank told them to? And why does the WHO keep adding new drugs every two years if the list is supposed to be ‘essential’? Sounds like they’re just trying to look relevant. Also - 10.5% fake meds? That’s not a flaw. That’s the system working exactly as intended. The WHO doesn’t care if your pills are real - they just want the paperwork to say they are.
Andrea Petrov
December 19, 2025 AT 08:36Ever wonder why the WHO never lists any drugs developed by non-Western companies? Or why every ‘essential’ medicine is patented by a Big Pharma subsidiary? This isn’t about access - it’s about control. The WHO is just the PR arm for the pharmaceutical industry’s global monopoly. They ‘prequalify’ generics - but only from manufacturers they’ve approved. Who approves them? The same agencies that take pharma money. This is a rigged game, and you’re all just chanting the hymn.
Suzanne Johnston
December 19, 2025 AT 16:49What’s striking isn’t the list itself - it’s how rarely we ask: who gets to decide what’s ‘essential’? Is it a human right to have insulin? Yes. But who defines ‘essential’? A panel of 25 experts from 18 countries? What about the millions of people whose diseases aren’t ‘prevalent enough’? What about mental health? Palliative care? The list doesn’t just reflect science - it reflects power. And until we admit that, we’re just rearranging deck chairs on the Titanic.
Graham Abbas
December 20, 2025 AT 17:36There’s poetry here. The WHO Model Formulary is like a lullaby for the world’s forgotten: ‘You deserve to live. You deserve this pill. It costs $2. We made sure of it.’ And yet - the world ignores the lullaby. We pour billions into space telescopes and AI chatbots, but when a child in Malawi coughs from pneumonia, we shrug because ‘the system didn’t deliver.’ The list isn’t perfect - but it’s the only thing that says: ‘No, this is not okay.’ And maybe that’s enough. For now.